OGN vs. GSK
Compare and contrast key facts about Organon & Co. (OGN) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: OGN or GSK.
Correlation
The correlation between OGN and GSK is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
OGN vs. GSK - Performance Comparison
Loading data...
Key characteristics
OGN:
-1.08
GSK:
-0.46
OGN:
-1.59
GSK:
-0.53
OGN:
0.78
GSK:
0.94
OGN:
-0.73
GSK:
-0.46
OGN:
-1.93
GSK:
-0.80
OGN:
28.66%
GSK:
16.50%
OGN:
51.56%
GSK:
27.34%
OGN:
-75.77%
GSK:
-54.70%
OGN:
-72.75%
GSK:
-14.13%
Fundamentals
OGN:
$2.28B
GSK:
$76.42B
OGN:
$3.14
GSK:
$2.02
OGN:
2.79
GSK:
18.63
OGN:
0.37
GSK:
2.42
OGN:
4.34
GSK:
4.07
OGN:
$6.29B
GSK:
$31.53B
OGN:
$3.60B
GSK:
$22.56B
OGN:
$1.50B
GSK:
$8.24B
Returns By Period
In the year-to-date period, OGN achieves a -38.15% return, which is significantly lower than GSK's 13.84% return.
OGN
-38.15%
-18.52%
-38.61%
-56.31%
N/A
N/A
GSK
13.84%
5.97%
15.44%
-12.60%
7.51%
6.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
OGN vs. GSK — Risk-Adjusted Performance Rank
OGN
GSK
OGN vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
OGN vs. GSK - Dividend Comparison
OGN's dividend yield for the trailing twelve months is around 9.51%, more than GSK's 4.30% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OGN Organon & Co. | 9.51% | 7.51% | 7.77% | 4.01% | 1.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GSK GlaxoSmithKline plc | 4.30% | 4.65% | 3.75% | 4.78% | 6.17% | 6.86% | 5.34% | 6.95% | 7.13% | 8.84% | 7.44% | 7.60% |
Drawdowns
OGN vs. GSK - Drawdown Comparison
The maximum OGN drawdown since its inception was -75.77%, which is greater than GSK's maximum drawdown of -54.70%. Use the drawdown chart below to compare losses from any high point for OGN and GSK. For additional features, visit the drawdowns tool.
Loading data...
Volatility
OGN vs. GSK - Volatility Comparison
Organon & Co. (OGN) has a higher volatility of 37.83% compared to GlaxoSmithKline plc (GSK) at 8.49%. This indicates that OGN's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
OGN vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Organon & Co. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
OGN vs. GSK - Profitability Comparison
OGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Organon & Co. reported a gross profit of 841.00M and revenue of 1.51B. Therefore, the gross margin over that period was 55.6%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a gross profit of 5.58B and revenue of 7.52B. Therefore, the gross margin over that period was 74.2%.
OGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Organon & Co. reported an operating income of 325.00M and revenue of 1.51B, resulting in an operating margin of 21.5%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported an operating income of 2.22B and revenue of 7.52B, resulting in an operating margin of 29.5%.
OGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Organon & Co. reported a net income of 87.00M and revenue of 1.51B, resulting in a net margin of 5.8%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a net income of 1.62B and revenue of 7.52B, resulting in a net margin of 21.6%.